Skip to content
Peptide research

Dulaglutide

Also known as Trulicity
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

An injectable GLP-1 receptor agonist for type 2 diabetes, also used off-label for weight loss. Unlike many peptides here, the case rests on large human trials, not animal or mechanism data: solid evidence for HbA1c reduction, weight loss, and cardiovascular risk reduction, with low hypoglycemia risk. Main concerns are common GI side effects and a theoretical, boxed-warning risk of thyroid tumors in rodents. FDA-approved (Trulicity), prescription-only.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Dulaglutide (brand name Trulicity) is an FDA-approved, once-weekly injectable GLP-1 receptor agonist developed by Eli Lilly for type 2 diabetes. It is a large fusion protein that mimics GLP-1, a natural hormone your body releases after eating that signals fullness, stimulates insulin release, and slows digestion. Two amino acid modifications make it resistant to the enzyme that normally breaks down GLP-1 in minutes, giving Trulicity a roughly 5-day half-life that allows once-weekly dosing. First approved by the FDA in September 2014, it has since received expanded approvals for cardiovascular risk reduction and pediatric use (ages 10+).

How it works in the body

Mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells, stimulating insulin release when blood sugar is high. In the brain, it activates GLP-1 receptors in appetite centers to reduce hunger. Its large Fc-antibody fragment extends its half-life to ~5 days.

Research overview

Dulaglutide has one of the most robust clinical evidence bases of any GLP-1 drug, anchored by the AWARD program — at least 11 Phase III trials across diverse patient populations. These trials consistently showed Trulicity was as good as or better than other diabetes medications including metformin, sitagliptin, exenatide, liraglutide, and insulin glargine at lowering blood sugar (HbA1c) and supporting weight management. The landmark REWIND cardiovascular outcomes trial (9,901 patients, median 5.4-year follow-up) demonstrated a 12% reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) with a hazard ratio of 0.88. Notably, REWIND was the first GLP-1 drug heart study to enroll mostly patients without pre-existing heart disease, suggesting broad heart-protective benefits beyond high-risk populations. Ongoing research is exploring potential benefits for fatty liver disease, kidney protection, and neurodegenerative conditions.

Who researches Dulaglutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    FDA boxed warning for thyroid C-cell tumor risk. Contraindicated in MTC/MEN2.

  • Those with History of pancreatitis

    High

    Monitor for and discontinue if pancreatitis occurs. Acute pancreatitis reported in trials.

  • Those with Severe gastroparesis

    High

    GLP-1 agonist slows gastric emptying. Avoid with severe gastroparesis.

  • Those with Severe renal impairment

    Moderate

    GI-related dehydration may worsen renal function. Monitor closely.

  • Those who are pregnant or breastfeeding

    Absolute

    Animal data shows fetal harm. Discontinue before conception.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    FDA boxed warning for thyroid C-cell tumor risk. Contraindicated in MTC/MEN2.

  • History of pancreatitis

    High

    Monitor for and discontinue if pancreatitis occurs. Acute pancreatitis reported in trials.

  • Severe gastroparesis

    High

    GLP-1 agonist slows gastric emptying. Avoid with severe gastroparesis.

  • Severe renal impairment

    Moderate

    GI-related dehydration may worsen renal function. Monitor closely.

General cautions

  • Pregnancy

    Absolute

    Pregnancy — precaution, not an absolute FDA contraindication. Animal studies suggest fetal risk; use during pregnancy only if the potential benefit justifies that risk.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(8)

Rated by level of concern

  • Gastrointestinal adverse events

    High

    Trulicity FDA prescribing information, Section 6.1; Frias JP et al., AWARD-11 (PMID 33397768)

  • Hypoglycemia (when combined with insulin or sulfonylureas)

    High

    Trulicity FDA prescribing information, Sections 2.1, 5.4 and 6.1

  • Gallbladder disease

    Moderate

    He L et al., JAMA Intern Med 2022;182:513-519 (PMID 35344001)

  • Pancreatitis

    Low

    Trulicity FDA prescribing information, Section 5.2; REWIND safety data, Lancet 2019;394:121-130 (PMID 31189511)

  • Acute kidney injury

    Low

    Trulicity FDA prescribing information, Section 5.5; Gerstein HC et al., REWIND renal outcomes, Lancet 2019;394:131-138 (PMID 31189509)

  • Serious hypersensitivity reactions

    Low

    Trulicity FDA prescribing information, Sections 4, 5.7 and 6.2

  • Cardiac conduction abnormalities

    Low

    Trulicity FDA prescribing information, Sections 6.1 and 12.2

  • Thyroid C-cell tumors (boxed warning)

    Theoretical

    Trulicity FDA prescribing information, Boxed Warning and Sections 4, 5.1, 13.1

Interaction summary(8)

Rated by direction with this peptide

  • Insulin (basal or prandial)

    CautionHigh

    Concomitant use substantially increases hypoglycemia risk; the label recommends reducing the insulin dose when dulaglutide is added, with careful glucose monitoring during titration.

    Trulicity FDA prescribing information, Sections 2.1 and 5.4

  • Sulfonylureas (glimepiride, glipizide, glyburide)

    CautionHigh

    Sulfonylureas stimulate insulin secretion independently of glucose, removing the glucose-dependence that normally limits hypoglycemia on a GLP-1 agonist; secretagogue dose reduction is advised when starting dulaglutide.

    Trulicity FDA prescribing information, Sections 2.1 and 5.4

  • General anesthesia and procedural sedation

    CautionModerate

    Delayed gastric emptying can leave residual gastric contents despite standard fasting. The 2023 ASA consensus-based guidance suggested considering holding weekly GLP-1 receptor agonists about one week before elective procedures; the 2024 multisociety guidance moved toward individualized risk assessment and a clear-liquid/point-of-care-ultrasound approach rather than routine withholding. Dulaglutide's ~5-day half-life makes the timing consequential either way. Evidence is case-series and expert consensus, not RCT.

    American Society of Anesthesiologists consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists (2023); multisociety clinical practice guidance (2024)

  • Oral medications with narrow therapeutic index (warfarin, levothyroxine, oral contraceptives)

    CautionLow

    Dulaglutide delays gastric emptying and can in principle alter oral drug absorption; dedicated PK studies found the effects small and not clinically meaningful, and no dose adjustment is required. Monitoring is prudent where a narrow therapeutic index applies (e.g. INR with warfarin).

    Trulicity FDA prescribing information, Sections 7.1 and 12.3

  • Volume-depleting or nephrotoxic agents (loop diuretics, ACE inhibitors/ARBs, NSAIDs)

    CautionLow

    This is clinical inference, not a labeled interaction. The label warns about acute kidney injury in the setting of dehydration from nausea, vomiting or diarrhea but does not name these drug classes. The reasoning - that during acute GI illness these agents compound the hemodynamic insult, so sick-day holding is sensible - is sound and widely taught, but rests on general nephrology principle rather than dulaglutide-specific data.

    Trulicity FDA prescribing information, Section 5.5 (AKI with volume depletion); general sick-day medication guidance

  • SGLT2 inhibitors

    SynergisticLow

    Complementary mechanisms give additive HbA1c and weight benefit without added hypoglycemia; the AWARD-10 randomized placebo-controlled trial showed dulaglutide added to an SGLT2 inhibitor significantly improved glycemic control versus placebo at 24 weeks.

    Ludvik B et al., AWARD-10, Lancet Diabetes Endocrinol 2018;6:370-381; NCT02597049

  • Metformin

    SynergisticLow

    No clinically relevant pharmacokinetic interaction requiring dose adjustment, and metformin is the standard background therapy in the AWARD program - additive glycemic effect with low hypoglycemia risk.

    Frias JP et al., AWARD-11 (PMID 33397768); Trulicity FDA prescribing information, Section 12.3

  • DPP-4 inhibitors (sitagliptin, linagliptin)

    CautionLow

    Mechanistically redundant - both act on the incretin axis - and combining them adds cost and GI burden without meaningful additional glycemic benefit, so co-prescription is generally not recommended. This is a guideline/consensus position on therapeutic redundancy, not a pharmacologic safety interaction.

    ADA Standards of Care in Diabetes, pharmacologic approaches to glycemic treatment (annual, Diabetes Care Supplement 1)

Known risks(8)

  • Thyroid C-cell tumors (boxed warning)

    Dose-related increase in thyroid C-cell tumors observed in rodent studies at lifetime exposure. Human relevance is unknown. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2. 15+ year postmarketing registry mandated by FDA.

  • Pancreatitis

    Acute pancreatitis reported in clinical trials and postmarketing. If suspected, dulaglutide should be promptly discontinued and not restarted. Meta-analyses have not confirmed a definitive causal relationship, but vigilance is warranted.

  • Gastrointestinal adverse events

    Most common class effect: nausea (12-21%), diarrhea (8-13%), vomiting (6-13%), abdominal pain (7-10%). REWIND: 47.4% GI events vs 34.1% placebo. Can lead to dehydration and acute kidney injury in susceptible patients.

  • Hypoglycemia (when combined with insulin or sulfonylureas)

    Low intrinsic hypoglycemia risk due to glucose-dependent mechanism, but risk increases significantly when combined with insulin secretagogues or exogenous insulin. Dose reduction of concomitant agents may be necessary.

  • Acute kidney injury

    Reports of acute renal failure and worsening chronic renal failure, sometimes requiring hemodialysis, often related to dehydration from severe GI adverse effects. Renal function should be monitored, especially in patients with existing renal impairment.

  • Gallbladder disease

    Cholelithiasis and cholecystitis reported in clinical trials and postmarketing surveillance. Patients should be counseled about symptoms of gallbladder disease.

  • Serious hypersensitivity reactions

    Anaphylaxis, angioedema, and serious systemic hypersensitivity reactions have been reported. Dulaglutide should be discontinued if a reaction occurs and not restarted.

  • Cardiac conduction abnormalities

    PR interval prolongation and first-degree atrioventricular (AV) block have been reported. No clinically significant QTc prolongation observed in dedicated studies.

Drug interactions(8)

  • Insulin (all formulations)

    Moderate

    Increased risk of hypoglycemia. Dose reduction of insulin may be needed when initiating or escalating dulaglutide.

  • Sulfonylureas (e.g., glipizide, glimepiride, glyburide)

    Moderate

    Increased risk of hypoglycemia. Consider reducing sulfonylurea dose when adding dulaglutide.

  • Warfarin

    Low-Moderate

    Dulaglutide delays warfarin Tmax and reduces Cmax by ~22% due to slowed gastric emptying. Not considered clinically significant, but more frequent INR monitoring is recommended as warfarin has a narrow therapeutic index.

  • Oral contraceptives

    Low

    Delayed gastric emptying may reduce rate of absorption. Studies with norgestimate/ethinyl estradiol showed Cmax reductions of 26% and 13% respectively, with no change in overall exposure (AUC). Clinical significance is low.

  • Oral medications with narrow therapeutic index

    Moderate

    Dulaglutide slows gastric emptying, potentially affecting absorption kinetics of concomitant oral medications. Drugs with narrow therapeutic windows require enhanced monitoring.

  • Metformin

    None (safe combination)

    No clinically significant pharmacokinetic interaction. Dulaglutide was studied extensively with metformin in AWARD trials.

  • Sitagliptin and other DPP-4 inhibitors

    Low (avoid combination)

    Using dulaglutide with DPP-4 inhibitors is not recommended, as both act on the GLP-1 pathway. Dulaglutide is resistant to DPP-4, so adding a DPP-4 inhibitor provides no additional incretin benefit and may increase GI side effects.

  • Acetaminophen (paracetamol)

    Low

    Dulaglutide delayed acetaminophen Tmax by 1 hour and reduced its Cmax by 36%. Overall exposure (AUC) was not significantly affected. Not clinically meaningful for most uses.

Research & benefits

Evidence base

Evidence Level
Level 1 — Strong
Total Studies
15
Human Participants
25000

Dulaglutide has strong cardiovascular outcomes evidence from REWIND (N=9,901; median follow-up 5.4 years), a large GLP-1 receptor agonist cardiovascular outcomes trial with long follow-up. The AWARD program includes 11+ phase III RCTs demonstrating consistent glycemic efficacy across monotherapy and combination therapy settings. Head-to-head trials have shown superiority over metformin, sitagliptin, and exenatide, and non-inferiority to liraglutide and insulin glargine.

Researched for(6)

Rated by confidence in the evidence

  • Glycemic control (HbA1c reduction)

    High

    Large randomized trials show dose-dependent HbA1c reductions of about 1.5 to 1.9 percent.

    Frias JP et al., AWARD-11, Diabetes Care 2021;44:765-773 (PMID 33397768)

  • Cardiovascular risk reduction

    High

    Dedicated cardiovascular trial showed modest risk reduction, driven mainly by fewer strokes.

    Gerstein HC et al., REWIND, Lancet 2019;394:121-130 (PMID 31189511); NCT01394952

  • Weight loss

    High

    Human trials show modest weight loss, about 3 to 5 kg, not FDA-approved for weight management.

    Frias JP et al., AWARD-11, Diabetes Care 2021;44:765-773 (PMID 33397768)

  • Low hypoglycemia risk

    High

    Low hypoglycemia risk alone or with metformin, but higher when combined with insulin or sulfonylureas.

    Frias JP et al., AWARD-11 (PMID 33397768); Trulicity (dulaglutide) FDA prescribing information, Sections 5.4 and 6.1

  • Once-weekly convenience

    Medium

    Once-weekly dosing reflects solid pharmacokinetic data, though convenience itself is not a measured trial outcome.

    Trulicity (dulaglutide) FDA prescribing information, Section 12.3 (pharmacokinetics)

  • Fasting and postprandial glucose reduction

    High

    Prespecified trial endpoints show consistent reductions in fasting and after-meal glucose levels.

    Frias JP et al., AWARD-11, Diabetes Care 2021;44:765-773 (PMID 33397768); Trulicity FDA prescribing information, Section 14

Benefits(6)

  • Glycemic control (HbA1c reduction)

    AWARD-1 through AWARD-11 trials showed HbA1c reductions of 0.7-1.6% across doses; AWARD-5 showed 1.1% reduction with 1.5 mg vs 0.4% with sitagliptin (p<0.001)

  • Cardiovascular risk reduction

    REWIND trial (N=9,901): 12% reduction in MACE (HR 0.88, 95% CI 0.79-0.99; p=0.026) over median 5.4-year follow-up

  • Weight loss

    AWARD trials demonstrated weight reductions of 1.4-3.1 kg with 0.75-1.5 mg doses; AWARD-11 showed further weight loss with 3.0 mg and 4.5 mg doses

  • Low hypoglycemia risk

    Glucose-dependent mechanism of action results in low hypoglycemia rates; 96% of patients in clinical trials did not experience confirmed glucose <54 mg/dL

  • Once-weekly convenience

    5-day half-life enables once-weekly dosing; steady state achieved in 2-4 weeks; demonstrated improved treatment adherence versus daily injectable GLP-1 RAs

  • Fasting and postprandial glucose reduction

    A clinical pharmacology study reported placebo-adjusted fasting and postprandial glucose reductions of 25.6 and 59.5 mg/dL, respectively, sustained after six weeks of treatment.

Key studies(6)

  1. Gerstein HC, Colhoun HM, Dagenais GR, et al.

    The Lancet

    2019

    Dulaglutide reduced MACE by 12% (HR 0.88, 95% CI 0.79-0.99; p=0.026). Primary composite: non-fatal MI, non-fatal stroke, or CV death occurred in 12.0% dulaglutide vs 13.4% placebo. All-cause mortality trended lower but was not significant (HR 0.90, 95% CI 0.80-1.01; p=0.067).

  2. Wysham C, Blevins T, Arakaki R, et al.

    Diabetes Care

    2014

    Dulaglutide 1.5 mg reduced HbA1c by 1.5% vs 1.0% with exenatide BID at 26 weeks (p<0.001). Both dulaglutide doses were superior to exenatide and placebo.

  3. Weinstock RS, Guerci B, Umpierrez G, et al.

    Diabetes, Obesity and Metabolism

    2015

    HbA1c changes were −0.99% with dulaglutide 1.5 mg versus −0.32% with sitagliptin; corresponding weight reductions were 2.88 versus 1.75 kg.

  4. Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al.

    Diabetes Care

    2014

    Both dulaglutide doses (0.75 mg: -0.7%, 1.5 mg: -0.8%) showed superior HbA1c reduction vs metformin (-0.6%) at 26 weeks (p<0.05). Comparable weight loss profiles.

  5. Branch KRH, Dagenais GR, Avezum A, et al.

    European Journal of Heart Failure

    2022

    Heart failure events were not significantly different between groups (dulaglutide 4.3% vs placebo 4.6%; HR 0.93, 95% CI 0.77-1.12; p=0.456). No increased risk of heart failure hospitalization.

  6. Fala L

    American Health & Drug Benefits

    2015

    Comprehensive review of dulaglutide pharmacology, clinical trials (AWARD program), and place in therapy. Concluded favorable efficacy-safety profile for once-weekly GLP-1 RA therapy.

What research suggests over time

  • Weeks 2-4

    AWARD trials

    A1c trending down within 4 weeks; appetite reduction and modest weight loss begin.

  • Months 2-3

    AWARD-5 (Diabetes Care 2014)

    HbA1c reduction of ~1.1-1.5% by 26 weeks; superior weight loss to sitagliptin (~3.1 kg).

  • Long-term

    Phase 3 CVOT

    12% MACE reduction over 5.4-year median follow-up in REWIND (n=9,901, Lancet 2019) — a large GLP-1 cardiovascular outcomes trial with long follow-up.

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Trulicity (dulaglutide)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(8)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • Fasting glucose + HbA1c

    Optimal 75–90 mg/dL

    Baseline metabolic markers — critical for tracking glucose regulation changes.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Optimal ApoB <80, TG <80, HDL >55

    Cholesterol and triglyceride baseline for tracking cardiovascular metabolic effects.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Thyroid panel (TSH, free T3/T4)

    Optimal TSH 1.0–2.0; Free T3 upper third of range

    Thyroid function can be affected by metabolic peptides.

    Lab normal TSH 0.4–4.5

  • Amylase + Lipase

    Optimal Both within mid-range

    Baseline pancreatic markers — this peptide carries a documented pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Optimal Under 5 pg/mL

    Baseline thyroid C-cell marker — this peptide carries a thyroid tumor risk warning.

    Lab normal Under 10 pg/mL (men)

  • ECG recommended

    Baseline cardiac rhythm assessment — QTc prolongation risk documented.

Ongoing tracking(5)

  • Fasting glucose + HbA1c

    Every 4-8 weeksOptimal 75–90 mg/dL

    Track glucose regulation changes during protocol.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Every 8-12 weeksOptimal ApoB <80, TG <80, HDL >55

    Monitor cholesterol and triglyceride response.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic function monitoring during metabolic modulation.

    Lab normal ALT 7–56, AST 10–40 U/L

  • Amylase + Lipase

    Every 8-12 weeksOptimal Both within mid-range

    Pancreatic enzyme monitoring — pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Every 12 weeksOptimal Under 5 pg/mL

    Thyroid C-cell monitoring — MTC risk.

    Lab normal Under 10 pg/mL (men)

Retest schedule(6)

  1. Baseline

    critical

    Before starting

    Full baseline + thyroid panel, lipase, amylase, HbA1c, lipid panel.

  2. Early follow-up

    critical

    Week 4

    Recheck lipase, amylase, glucose. Most early-protocol concerns surface here.

  3. Second check

    critical

    Week 8

    Recheck metabolic markers and GI tolerance.

  4. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Track HbA1c, weight, lipids, thyroid.

  5. Ongoing

    standard

    Every 12 weeks

    Sustained metabolic monitoring during chronic use.

  6. Post-protocol

    standard

    4-6 weeks after stopping

    Track for weight regain and metabolic rebound.

When to stop and reassess(7)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Lipase or amylase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — possible pancreatitis.

  • Calcitonin

    consult

    Above 10 pg/mL or rising trend

    Consult an endocrinologist — possible thyroid C-cell stimulation.

  • Heart rate

    consult

    Sustained >100 bpm or new palpitations

    Consult a provider — GLP-1 agonists can affect cardiac rhythm.

  • Lipase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — pancreatitis risk documented.

Lab monitoring helps track your body's response to Dulaglutide. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

The REWIND trial — 9,901 patients over 5.4 years — showed a 12% reduction in major cardiovascular events, uniquely in patients mostly without pre-existing heart disease. While newer GLP-1 drugs like semaglutide produce greater weight loss, dulaglutide's 11+ Phase III trials and long safety track record keep it clinically relevant. Ongoing research into liver and kidney protection may further expand its profile.

Estimated cost
$900-1,100/mo retail (Trulicity); insurance may cover
FDA status
FDA-approved (BLA 125469). Initially approved September 18, 2014, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Label expanded in 2020 to include additional doses. Cardiovascular risk reduction indication added based on REWIND trial data. Pediatric indication (ages 10+) approved in 2022. Current indications are improving glycemic control in adults and pediatric patients aged 10+ with type 2 diabetes, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies.
WADA status
Not specifically prohibited. GLP-1 receptor agonists are not currently on the WADA Prohibited List. However, WADA placed semaglutide on its Monitoring Program starting in 2024 and has funded analytical method development for GLP-1 RAs (including semaglutide, liraglutide, and tirzepatide). While dulaglutide is not specifically named, WADA is actively studying the class for potential performance-enhancing effects (primarily via weight/body composition changes). Athletes should be aware that GLP-1 RAs could potentially move from monitoring to prohibition in future updates.
Prescribability
Yes — FDA-approved prescription medication for type 2 diabetes mellitus
Availability
Widely available by prescription in the United States and globally. Marketed as Trulicity by Eli Lilly. Available as single-dose prefilled pens. Administered via once-weekly subcutaneous injection. Approved in the US, EU, Japan, and many other countries. Cost is approximately $690-$1,000 per month without insurance in the US. Covered by most major insurance plans and Medicare Part D. Patient assistance programs are available through Eli Lilly.

International status

  • EU

    EMA-approved

  • UK

    MHRA-approved

  • US

    FDA-approved (Trulicity)

  • Canada

    Health Canada-approved

  • Australia

    TGA-approved

Regulatory timeline(8)

  1. 2014-09-18
    FDA initial approval (BLA 125469) for Trulicity 0.75 mg and 1.5 mg as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes
  2. 2014-11
    EU marketing authorization (EMA) granted for Trulicity
  3. 2015-07-03
    Approved in Japan for type 2 diabetes. Commercial launch followed on September 16, 2015.
  4. 2017
    Supplemental label updates based on additional AWARD trial data
  5. 2020-02
    FDA approved expanded cardiovascular indication: reduction of MACE in adults with T2D and established CVD or multiple CV risk factors (based on REWIND trial)
  6. 2020-09-03
    FDA approved higher doses (3.0 mg and 4.5 mg) based on AWARD-11 data
  7. 2022
    FDA approved supplemental BLA for pediatric indication (patients aged 10 years and older with type 2 diabetes)
  8. 2025
    Updated prescribing information (label revision s063) reflecting cumulative postmarketing safety data

Sources & FAQs

Research sources(8)

Frequently asked questions(6)

How does dulaglutide differ from semaglutide (Ozempic/Wegovy)?

Both are once-weekly GLP-1 receptor agonists, but they differ in molecular structure. Dulaglutide is a GLP-1-IgG4 Fc fusion protein (~57 kDa) while semaglutide is an acylated GLP-1 analog (~4.1 kDa) that binds to albumin. Clinical trials suggest semaglutide may produce greater HbA1c reduction and weight loss at comparable doses, but dulaglutide has the longest cardiovascular outcomes trial data (REWIND: 5.4-year median follow-up, N=9,901).

What are the most common side effects?

Gastrointestinal side effects are most common: nausea (12-21%), diarrhea (8-13%), vomiting (6-13%), abdominal pain (7-10%), and decreased appetite (5-10%). These are typically mild-to-moderate, occur most frequently during initiation/dose escalation, and tend to diminish over time. In the REWIND trial, 47.4% of dulaglutide patients reported any GI adverse event vs 34.1% on placebo.

Is dulaglutide approved for weight loss?

No. Dulaglutide (Trulicity) is FDA-approved only for type 2 diabetes management and cardiovascular risk reduction. While weight loss is a consistent effect in clinical trials (1.4-3.1 kg), it is not approved for obesity or weight management, unlike semaglutide (Wegovy) and liraglutide (Saxenda), which have separate obesity indications.

Can dulaglutide be used with insulin?

Yes. Dulaglutide has been studied in combination with basal insulin (AWARD-9) and prandial insulin. When adding dulaglutide to insulin therapy, or vice versa, the dose of insulin may need to be reduced to minimize hypoglycemia risk. Combination with insulin secretagogues (e.g., sulfonylureas) also requires dose reduction consideration.

How long does it take to work?

Dulaglutide begins lowering blood glucose with the first dose. Peak plasma concentration is reached in 24-72 hours (median 48 hours). Steady-state levels are achieved in 2-4 weeks of weekly dosing. Meaningful HbA1c reductions are typically observed by 4-8 weeks, with maximum effect at 12-26 weeks. The accumulation ratio at steady state is approximately 1.56.

Is there a risk of thyroid cancer?

In rodent studies, dulaglutide caused dose-related thyroid C-cell tumors. However, the EMA's Pharmacovigilance Risk Assessment Committee concluded in 2023 that there is no evidence of a causal relationship between GLP-1 RAs and thyroid cancer in humans. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A 15+ year postmarketing thyroid carcinoma registry is ongoing as required by the FDA.